期刊
PLOS ONE
卷 9, 期 9, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0106748
关键词
-
资金
- Catalan Institute of Oncology (ICO)
- Private Foundation of the Biomedical Research Institute of Bellvitge (IDIBELL)
- Instituto de Salud Carlos III [PI08-1635, PI08-1359, PS09-1037, PI11-1439]
- CIBERESP [CB06/02/2005]
- Accion Transversal del Cancer
- Catalan Government DURSI [2009SGR1489]
- Fundacio Privada Olga Torres (FOT)
- Spanish Association Against Cancer (AECC) Scientific Foundation
- European Commission [FP7-COOP-Health-2007-B]
- Xarxa de Bancs de Tumors de Catalunya - Pla Director d'Oncologia de Catalunya (XBTC)
Background: Accurate detection of characteristic proteins secreted by colon cancer tumor cells in biological fluids could serve as a biomarker for the disease. The aim of the present study was to identify and validate new serum biomarkers and demonstrate their potential usefulness for early diagnosis of colon cancer. Methods: The study was organized in three sequential phases: 1) biomarker discovery, 2) technical and biological validation, and 3) proof of concept to test the potential clinical use of selected biomarkers. A prioritized subset of the differentially-expressed genes between tissue types (50 colon mucosa from cancer-free individuals and 100 normal-tumor pairs from colon cancer patients) was validated and further tested in a series of serum samples from 80 colon cancer cases, 23 patients with adenoma and 77 cancer-free controls. Results: In the discovery phase, 505 unique candidate biomarkers were identified, with highly significant results and high capacity to discriminate between the different tissue types. After a subsequent prioritization, all tested genes (N = 23) were successfully validated in tissue, and one of them, COL10A1, showed relevant differences in serum protein levels between controls, patients with adenoma (p = 0.0083) and colon cancer cases (p = 3.2e-6). Conclusion: We present a sequential process for the identification and further validation of biomarkers for early detection of colon cancer that identifies COL10A1 protein levels in serum as a potential diagnostic candidate to detect both adenoma lesions and tumor. Impact: The use of a cheap serum test for colon cancer screening should improve its participation rates and contribute to decrease the burden of this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据